Sign Out
Pharmacology: Pharmacokinetics: Cefpodoxime proxetil is the prodrug of cefpodoxime and is de-esterified in the intestinal epithelium after oral doses, to release active Cefpodoxime in the bloodstream. Bioavailability is about 50% in fasting subjects and may be increased in the presence of food.
Absorption is decreased in conditions of low gastric acidity. Peak plasma concentrations of about 1.5, 2.5, and 4.0 micrograms/mL have been achieved 2 to 3 hours after oral doses of 100, 200 and 400 mg Cefpodoxime respectively. About 20 to 30% of Cefpodoxime is bound to plasma proteins. The plasma half-life is about 2 to 3 hours and is prolonged in patients with renal impairment.
Cefpodoxime reaches therapeutic concentrations in the respiratory and genito-urinary tracts and bile. It has been detected in low concentrations in breast milk.
Cefpodoxime is excreted unchanged in the urine. Some is removed by dialysis.
